Cadrenal CEO Pham to present at Lytham Fall 2026 conference Sept. 29
Ponte Vedra – October 27, 2026 -- Cadrenal Therapeutics (Nasdaq: CVKD) will put CEO Quang X. Pham in front of investors at 10:15 a.m. ET on Tuesday, September 29, 2026, with a webcast presentation at the Lytham Partners Fall 2026 Investor Conference.
Two-day virtual conference includes one-on-one investor meetings
The conference runs virtually on September 29-30, 2026. Management will hold one-on-one meetings throughout the event. Investors can arrange them through Lytham Partners or by registering for the conference. A replay of the webcast will be available after the event.
CAD-1005 holds FDA and EMA designations in heparin-induced thrombocytopenia
Cadrenal describes itself as a late-stage biopharmaceutical company focused on critical care cardiology and orphan cardiovascular conditions. Its pipeline includes CAD-1005, tecarfarin and frunexian.